Florien W Boele1, Maaike Zant1, Emma C E Heine1, Neil K Aaronson1, Martin J B Taphoorn1, Jaap C Reijneveld1, Tjeerd J Postma1, Jan J Heimans1, Martin Klein1. 1. Department of Medical Psychology , VU University Medical Center , Amsterdam, the Netherlands (F.W.B., M.Z., E.C.E.H., M.K.); Department of Neurology , VU University Medical Center , Amsterdam, the Netherlands (J.J.H., T.J.P., J.C.R.); Department of Neurology , Medical Center Haaglanden , The Hague, the Netherlands (M.J.B.T.); Division of Psychosocial Research and Epidemiology , The Netherlands Cancer Institute , Amsterdam , the Netherlands (N.K.A.).
Abstract
BACKGROUND: Glioma patients are not only confronted with the diagnosis and treatment of a brain tumor, but also with changes in cognitive and neurological functioning that can profoundly affect their daily lives. At present, little is known about the relationship between cognitive functioning and health-related quality of life (HRQOL) during the disease trajectory. We studied this association in low-grade glioma (LGG) patients with stable disease at an average of 6 years after diagnosis. METHODS: Patients and healthy controls underwent neuropsychological testing and completed self-report measures of generic (MOS SF36) and disease-specific (EORTC BN20) HRQOL. Associations were determined with Pearson correlations, and corrections for multiple testing were made. RESULTS: We analyzed data gathered from 190 LGG patients. Performance in all cognitive domains was positively associated with physical health (SF36 Physical Component Summary). Executive functioning, processing speed, working memory, and information processing were positively associated with mental health (SF36 Mental Component Summary). We found negative associations between a wide range of cognitive domains and disease-specific HRQOL scales. CONCLUSIONS: In stable LGG patients, poorer cognitive functioning is related to lower generic and disease-specific HRQOL. This confirms that cognitive assessment of LGG patients should not be done in isolation from assessment of its impact on HRQOL, both in clinical and in research settings.
BACKGROUND:Gliomapatients are not only confronted with the diagnosis and treatment of a brain tumor, but also with changes in cognitive and neurological functioning that can profoundly affect their daily lives. At present, little is known about the relationship between cognitive functioning and health-related quality of life (HRQOL) during the disease trajectory. We studied this association in low-grade glioma (LGG) patients with stable disease at an average of 6 years after diagnosis. METHODS:Patients and healthy controls underwent neuropsychological testing and completed self-report measures of generic (MOS SF36) and disease-specific (EORTC BN20) HRQOL. Associations were determined with Pearson correlations, and corrections for multiple testing were made. RESULTS: We analyzed data gathered from 190 LGG patients. Performance in all cognitive domains was positively associated with physical health (SF36 Physical Component Summary). Executive functioning, processing speed, working memory, and information processing were positively associated with mental health (SF36 Mental Component Summary). We found negative associations between a wide range of cognitive domains and disease-specific HRQOL scales. CONCLUSIONS: In stable LGG patients, poorer cognitive functioning is related to lower generic and disease-specific HRQOL. This confirms that cognitive assessment of LGG patients should not be done in isolation from assessment of its impact on HRQOL, both in clinical and in research settings.
Authors: N K Aaronson; M Muller; P D Cohen; M L Essink-Bot; M Fekkes; R Sanderman; M A Sprangers; A te Velde; E Verrips Journal: J Clin Epidemiol Date: 1998-11 Impact factor: 6.437
Authors: Martin L Waagemans; David van Nieuwenhuizen; Monica Dijkstra; Miriam Wumkes; Clemens M F Dirven; Sieger Leenstra; Jaap C Reijneveld; Martin Klein; Lukas J A Stalpers Journal: Neurosurgery Date: 2011-07 Impact factor: 4.654
Authors: Derek R Johnson; Allison M Sawyer; Christina A Meyers; Brian Patrick O'Neill; Jeffrey S Wefel Journal: Neuro Oncol Date: 2012-04-16 Impact factor: 12.300
Authors: M Klein; J J Heimans; N K Aaronson; H M van der Ploeg; J Grit; M Muller; T J Postma; J J Mooij; R H Boerman; G N Beute; G J Ossenkoppele; G W van Imhoff; A W Dekker; J Jolles; B J Slotman; H Struikmans; M J B Taphoorn Journal: Lancet Date: 2002-11-02 Impact factor: 79.321
Authors: M J van den Bent; J S Wefel; D Schiff; M J B Taphoorn; K Jaeckle; L Junck; T Armstrong; A Choucair; A D Waldman; T Gorlia; M Chamberlain; B G Baumert; M A Vogelbaum; D R Macdonald; D A Reardon; P Y Wen; S M Chang; A H Jacobs Journal: Lancet Oncol Date: 2011-04-05 Impact factor: 41.316
Authors: Martin Klein; Nadine H J Engelberts; Henk M van der Ploeg; Dorotheé G A Kasteleijn-Nolst Trenité; Neil K Aaronson; Martin J B Taphoorn; Hans Baaijen; W Peter Vandertop; Martin Muller; Tjeerd J Postma; Jan J Heimans Journal: Ann Neurol Date: 2003-10 Impact factor: 10.422
Authors: Mirjam Renovanz; Sari Soebianto; Helena Tsakmaklis; Naureen Keric; Minou Nadji-Ohl; Manfred Beutel; Florian Ringel; Daniel Wollschläger; Anne-Katrin Hickmann Journal: Support Care Cancer Date: 2019-03-23 Impact factor: 3.603
Authors: Ben Rimmer; Iakov Bolnykh; Lizzie Dutton; Joanne Lewis; Richéal Burns; Pamela Gallagher; Sophie Williams; Vera Araújo-Soares; Fiona Menger; Linda Sharp Journal: Qual Life Res Date: 2022-08-06 Impact factor: 3.440
Authors: Divine E Ediebah; Jaap C Reijneveld; Martin J B Taphoorn; Corneel Coens; Efstathios Zikos; Neil K Aaronson; Jan J Heimans; Andrew Bottomley; Martin Klein Journal: Qual Life Res Date: 2016-10-15 Impact factor: 4.147
Authors: Hugo Câmara-Costa; Kim S Bull; Colin Kennedy; Andreas Wiener; Gabriele Calaminus; Anika Resch; Virginie Kieffer; Clémence Lalande; Geraldina Poggi; Katja von Hoff; Jacques Grill; François Doz; Stefan Rutkowski; Maura Massimino; Rolf-Dieter Kortmann; Birgitta Lannering; Georges Dellatolas; Mathilde Chevignard Journal: Neurooncol Pract Date: 2017-02-10
Authors: Mia Salans; Michelle D Tibbs; Minh-Phuong Huynh-Le; Anthony Yip; Kathryn Tringale; Roshan Karunamuni; Ronghui Xu; Anny Reyes; Anna Christina Macari; Tonya Pan-Weisz; Carrie R McDonald; Jona A Hattangadi-Gluth Journal: Int J Radiat Oncol Biol Phys Date: 2021-06-06 Impact factor: 7.038
Authors: Matthijs van der Meulen; Linda Dirven; Esther J J Habets; Katerina Bakunina; Marion Smits; Hakim C Achterberg; Tatjana Seute; Gavin Cull; Harry Schouten; Josée M Zijlstra; Dieta Brandsma; Roelien H Enting; Max Beijert; Martin J B Taphoorn; Martin J van den Bent; Samar Issa; Jeanette K Doorduijn; Jacoline E C Bromberg Journal: Neuro Oncol Date: 2021-08-02 Impact factor: 12.300
Authors: Pia Banerjee; Kevin Leu; Robert J Harris; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Whitney B Pope; Susan Y Bookheimer; Benjamin M Ellingson Journal: Neuroimage Clin Date: 2015-10-23 Impact factor: 4.881